✦ LIBER ✦

Visual toxicity following intra-arterial chemotherapy with hydroxyethyl-CNU in patients with malignant gliomas

✍ Scribed by G. Defer; F. Fauchon; M. Schaison; J. Chiras; P. Brunet

Publisher: Springer
Year: 1991
Tongue: English
Weight: 630 KB
Volume: 33
Category: Article
ISSN: 0028-3940
DOI: 10.1007/bf00598619

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Selective intra-arterial chemotherapy wi

Selective intra-arterial chemotherapy with BCNU in recurrent malignant gliomas

✍ G. B. Bradac; R. Soffietti; A. Riva; G. Stura; S. Sales; D. Schiffer 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 883 KB

A reappraisal of intra-arterial chemothe

A reappraisal of intra-arterial chemotherapy. Results obtained in 145 patients with head and neck cancer treated during 1963-1966 with intra-arterial chemotherapy followed by radical radiotherapy

✍ C. Nervi; G. Arcangeli; C. Casale; M. Cortese; A. Guadagni; V. Le Pera 📂 Article 📅 1970 🏛 John Wiley and Sons 🌐 English ⚖ 431 KB 👁 2 views

I strated49 5. 7, 10, 11 that protracted intraarterial Chemotherapy with cytotoxic agents is particularly effective in shrinking or causing transient complete regression in cancer. Rest results have been observed in head and neck, limb, and liver cancer, as the specific vascularization of these area

Hyperfractionated radiation therapy (hfx

Hyperfractionated radiation therapy (hfx rt) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: A phase II study

✍ Branislav Jeremic; Danica Grujicic; Vaso Antunovic; Ljubodrag Djuric; Miroslav S 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 885 KB

Intensive chemotherapy with high doses o

Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies

✍ M. H. Gaspard; D. Maraninchi; A. M. Stoppa; J. A. Gastaut; G. Michel; N. Tubiana 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 688 KB

Twenty-six patients (median age 33 years) with poor-risk malignancies were treated with high-dose combination chemotherapy associating BCNU-etoposide-cytosine arabinoside and melphalan (BEAM) followed by autologous bone marrow transplantation (ABMT). Twenty-one patients had malignant lymphomas, thre